BACKGROUND: Peanut allergy represents a significant health threat in the United States. The factors contributing to the severity of the allergic response and the immunopathogenic mechanisms underlying peanut allergy remain to be completely characterized. As yet, no animal model has been developed that will completely mimic the physical, immunologic, and histologic features of food allergy. OBJECTIVE: The purpose of this investigation was to develop a neonatal pig model of peanut allergy that would mimic the allergic symptoms and the immunologic and histologic profile of human peanut allergy. METHODS: Newborn piglets sensitized intraperitoneally with peanut extract and cholera toxin were orally challenged repeatedly with peanut meal. Physical symptoms, including emesis, lethargy, diarrhea, and respiratory distress, were monitored to determine the allergic response. Immunologic assessment was conducted through use of skin testing and the antigenic response to peanut proteins. Histologically, tissues derived from the esophagus, stomach, small intestine, and colon were assessed for morphologic changes after the oral challenge. RESULTS: Peanut-sensitized pigs responded with physical symptoms that mimicked those seen in double-blinded, placebo-controlled oral food challenges to peanuts in children and adults. Skin testing suggested an IgE-mediated response; this was confirmed by a negative passive cutaneous anaphylaxis response of heat-treated sera obtained from peanut-sensitized animals. Damage to villi of the small intestine was similar to that seen in endoscopically obtained tissue specimens from certain food-allergic individuals. CONCLUSION: The neonatal pig model of peanut allergy mimics the physical and immunologic characteristics of peanut allergy in human beings. The model will be useful for determining IgE-mediated mechanisms and conducting endoscopic histologic assessment of tissues and immunotherapeutic intervention strategies with repeated allergen challenges.
BACKGROUND:Peanutallergy represents a significant health threat in the United States. The factors contributing to the severity of the allergic response and the immunopathogenic mechanisms underlying peanutallergy remain to be completely characterized. As yet, no animal model has been developed that will completely mimic the physical, immunologic, and histologic features of food allergy. OBJECTIVE: The purpose of this investigation was to develop a neonatal pig model of peanutallergy that would mimic the allergic symptoms and the immunologic and histologic profile of humanpeanutallergy. METHODS: Newborn piglets sensitized intraperitoneally with peanut extract and cholera toxin were orally challenged repeatedly with peanut meal. Physical symptoms, including emesis, lethargy, diarrhea, and respiratory distress, were monitored to determine the allergic response. Immunologic assessment was conducted through use of skin testing and the antigenic response to peanut proteins. Histologically, tissues derived from the esophagus, stomach, small intestine, and colon were assessed for morphologic changes after the oral challenge. RESULTS:Peanut-sensitized pigs responded with physical symptoms that mimicked those seen in double-blinded, placebo-controlled oral food challenges to peanuts in children and adults. Skin testing suggested an IgE-mediated response; this was confirmed by a negative passive cutaneous anaphylaxis response of heat-treated sera obtained from peanut-sensitized animals. Damage to villi of the small intestine was similar to that seen in endoscopically obtained tissue specimens from certain food-allergic individuals. CONCLUSION: The neonatal pig model of peanutallergy mimics the physical and immunologic characteristics of peanutallergy in human beings. The model will be useful for determining IgE-mediated mechanisms and conducting endoscopic histologic assessment of tissues and immunotherapeutic intervention strategies with repeated allergen challenges.
Authors: Nathalie J Plundrich; Andrew R Smith; Luke B Borst; Douglas B Snider; Tobias Käser; Evan S Dellon; Anthony T Blikslager; Jack Odle; Mary Ann Lila; Scott M Laster Journal: Clin Exp Allergy Date: 2019-11-26 Impact factor: 5.018
Authors: C F Inman; K Haverson; S R Konstantinov; P H Jones; C Harris; H Smidt; B Miller; M Bailey; C Stokes Journal: Clin Exp Immunol Date: 2010-02-22 Impact factor: 4.330
Authors: Romy Fischer; Jerry R McGhee; Huong Lan Vu; T Prescott Atkinson; Raymond J Jackson; Daniel Tomé; Prosper N Boyaka Journal: Am J Pathol Date: 2005-12 Impact factor: 4.307
Authors: Stefan G Buzoianu; Maria C Walsh; Mary C Rea; Orla O'Donovan; Eva Gelencsér; Gabriella Ujhelyi; Erika Szabó; Andras Nagy; R Paul Ross; Gillian E Gardiner; Peadar G Lawlor Journal: PLoS One Date: 2012-10-16 Impact factor: 3.240
Authors: Jenna L Van Gramberg; Michael J de Veer; Robyn E O'Hehir; Els N T Meeusen; Robert J Bischof Journal: PLoS One Date: 2012-12-19 Impact factor: 3.240
Authors: Celina G Vega; Marina Bok; Anastasia N Vlasova; Kuldeep S Chattha; Fernando M Fernández; Andrés Wigdorovitz; Viviana G Parreño; Linda J Saif Journal: PLoS One Date: 2012-08-03 Impact factor: 3.240